Blockade of Interleukin Seventeen (IL-17A) with Secukinumab in Hospitalized COVID-19 patients – the BISHOP study
ABSTRACT Background Patients with severe COVID-19 seem to have a compromised antiviral response and hyperinflammation. Neutrophils are critical players in COVID-19 pathogenesis. IL-17A plays a major role in protection against extracellular pathogens and neutrophil attraction and activation. We hypothesized that secukinumab, an anti-IL17A monoclonal antibody, could mitigate the deleterious hyperinflammation in COVID-19.Methods BISHOP was an open-label, single-center, phase-II controlled trial. Fifty adults hospitalized Covid-19 patients, confirmed by a positive SARS-CoV-2 RT-PCR, were randomized 1:1 to receive 300mg of secukinumab subcutaneously at day-0 (group A) plus standard of care (SoC: antiviral drugs, antimicrobials, corticosteroids, and/or anticoagulants) or SoC alone (group B). A second dose of 300mg of secukinumab could be administered on day-7, according to staff judgment. The primary endpoint was ventilator-free days at day-28 (VFD-28). Secondary efficacy and safety outcomes were also explored.Findings An intention-to-treat analysis showed no difference in VFD-28: 23.7 (95%CI 19.6-27.8) in group A vs. 23.8 (19.9-27.6) in group B, p=0.62; There was also no difference in hospitalization time, intensive care unit demand, the incidence of circulatory shock, acute kidney injury, fungal or bacterial co-infections, and severe adverse events. Pulmonary thromboembolism was less frequent in group A (4.2% vs. 26.2% p=0.04). There was one death in each group. Viral clearance, defined by the viral load fold change (2-ΔΔCT) in upper airways, between day-0 and day-7, was also similar: 0.17 (0.05-0.56) in group A vs. 0.24 (0.10-0.57) in group B.Interpretation The efficacy of secukinumab in the treatment of Covid19 was not demonstrated. No difference between groups in adverse events and no unexpected events were observed.Funding Novartis Brazil supported this research providing expert input in the development of the project, drug supply, data management, and monitoring..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
bioRxiv.org - (2023) vom: 05. Jan. Zur Gesamtaufnahme - year:2023 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Resende, Gustavo Gomes [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
|---|
| doi: |
10.1101/2021.07.21.21260963 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XBI032246994 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XBI032246994 | ||
| 003 | DE-627 | ||
| 005 | 20230429100556.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210724s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2021.07.21.21260963 |2 doi | |
| 035 | |a (DE-627)XBI032246994 | ||
| 035 | |a (biorXiv)10.1101/2021.07.21.21260963 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Resende, Gustavo Gomes |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Blockade of Interleukin Seventeen (IL-17A) with Secukinumab in Hospitalized COVID-19 patients – the BISHOP study |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a ABSTRACT Background Patients with severe COVID-19 seem to have a compromised antiviral response and hyperinflammation. Neutrophils are critical players in COVID-19 pathogenesis. IL-17A plays a major role in protection against extracellular pathogens and neutrophil attraction and activation. We hypothesized that secukinumab, an anti-IL17A monoclonal antibody, could mitigate the deleterious hyperinflammation in COVID-19.Methods BISHOP was an open-label, single-center, phase-II controlled trial. Fifty adults hospitalized Covid-19 patients, confirmed by a positive SARS-CoV-2 RT-PCR, were randomized 1:1 to receive 300mg of secukinumab subcutaneously at day-0 (group A) plus standard of care (SoC: antiviral drugs, antimicrobials, corticosteroids, and/or anticoagulants) or SoC alone (group B). A second dose of 300mg of secukinumab could be administered on day-7, according to staff judgment. The primary endpoint was ventilator-free days at day-28 (VFD-28). Secondary efficacy and safety outcomes were also explored.Findings An intention-to-treat analysis showed no difference in VFD-28: 23.7 (95%CI 19.6-27.8) in group A vs. 23.8 (19.9-27.6) in group B, p=0.62; There was also no difference in hospitalization time, intensive care unit demand, the incidence of circulatory shock, acute kidney injury, fungal or bacterial co-infections, and severe adverse events. Pulmonary thromboembolism was less frequent in group A (4.2% vs. 26.2% p=0.04). There was one death in each group. Viral clearance, defined by the viral load fold change (2-ΔΔCT) in upper airways, between day-0 and day-7, was also similar: 0.17 (0.05-0.56) in group A vs. 0.24 (0.10-0.57) in group B.Interpretation The efficacy of secukinumab in the treatment of Covid19 was not demonstrated. No difference between groups in adverse events and no unexpected events were observed.Funding Novartis Brazil supported this research providing expert input in the development of the project, drug supply, data management, and monitoring. | ||
| 650 | 4 | |a Biology |7 (dpeaa)DE-84 | |
| 650 | 4 | |a 570 |7 (dpeaa)DE-84 | |
| 700 | 1 | |a da Cruz Lage, Ricardo |e verfasserin |4 aut | |
| 700 | 1 | |a Lobê, Samara Quadros |e verfasserin |4 aut | |
| 700 | 1 | |a Medeiros, Amanda Fonseca |e verfasserin |4 aut | |
| 700 | 1 | |a Costa e Silva, Alessandra Dias |e verfasserin |4 aut | |
| 700 | 1 | |a Nogueira Sá, Antônio Tolentino |e verfasserin |4 aut | |
| 700 | 1 | |a Oliveira, Argenil José de Assis |e verfasserin |4 aut | |
| 700 | 1 | |a Sousa, Denise |e verfasserin |4 aut | |
| 700 | 1 | |a Guimarães, Henrique Cerqueira |e verfasserin |4 aut | |
| 700 | 1 | |a Gomes, Isabella Coelho |e verfasserin |4 aut | |
| 700 | 1 | |a Souza, Renan Pedra |e verfasserin |4 aut | |
| 700 | 1 | |a Aguiar, Renato Santana |e verfasserin |4 aut | |
| 700 | 1 | |a Tunala, Roberto |e verfasserin |4 aut | |
| 700 | 1 | |a Forestiero, Francisco |e verfasserin |4 aut | |
| 700 | 1 | |a Bueno Filho, Julio Silvio Souza |e verfasserin |4 aut | |
| 700 | 1 | |a Teixeira, Mauro Martins |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2023) vom: 05. Jan. |
| 773 | 1 | 8 | |g year:2023 |g day:05 |g month:01 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2021.07.21.21260963 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XBI | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 05 |c 01 | ||